Patents by Inventor Denice M. Spero

Denice M. Spero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidine derivatives useful as inhibitors of PKC-theta
    Patent number: 7550473
    Abstract: Disclosed are novel compounds of formula (I): wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: June 23, 2009
    Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Mario G. Cardozo, Derek Cogan, Charles Lawrence Cywin, George Dahmann, Darren DiSalvo, John David Ginn, Anthony S. Prokopowicz, III, Denice M. Spero, Erick Richard Roush Young
  • Substituted tricyclic heterocycles and their uses
    Patent number: 7291733
    Abstract: Disclosed are substituted tricyclic heterocycle compounds of the formulas (I), (II) and (III) shown below, wherein R1, R2, R3 and R4 are described herein, which are active as anti-inflammatory agents.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: November 6, 2007
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles Lawrence Cywin, Roman Wolfgang Fleck, Eugene Richard Hickey, Weimin Liu, Tina Marie Morwick, John Robert Proudfoot, Denice M. Spero
  • Cyanamides useful as reversible inhibitors of cysteine proteases
    Patent number: 6878706
    Abstract: Compounds according to the following formula (I): wherein the variables Q and R1 to R6 are as described herein, which reversibly inhibit the cysteine proteases, such as cathepsins K, S, F, L and B; pharmaceutical compositions containing such compounds, and method of treating diseases and pathological conditions exacerbated by these cysteine proteases such as, but not limited to rheumatoid arthritis, multiple sclerosis and other autoimmune diseases, osteoporosis, asthma, Alzheimer's disease, atherosclerosis and endometriosis.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: April 12, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals Inc.
    Inventors: Thomas A. Gilmore, Eugene Richard Hickey, Weimin Liu, Peter Allen Nemoto, Denice M. Spero
  • Compounds useful as reversible inhibitors of cysteine proteases
    Patent number: 6858623
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: May 29, 2003
    Date of Patent: February 22, 2005
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Pyrimidine derivatives useful as inhibitors of PKC-theta
    Publication number: 20040242613
    Abstract: Disclosed are novel compounds of formula (I): 1
    Type: Application
    Filed: January 27, 2004
    Publication date: December 2, 2004
    Applicants: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Mario G. Cardozo, Derek Cogan, Charles Lawrence Cywin, Georg Dahmann, Darren DiSalvo, John David Ginn, Anthony S. Prokopowicz, Denice M. Spero, Erick Young
  • Compounds useful as reversible inhibitors of cysteine proteases
    Patent number: 6787540
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: September 7, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Compounds useful as reversible inhibitors of cathespin S
    Patent number: 6730671
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes, for making such novel compounds.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: May 4, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Compounds useful as reversible inhibitors of cysteine proteases
    Patent number: 6720319
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: October 1, 2002
    Date of Patent: April 13, 2004
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Weimin Liu, Denice M. Spero, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20040006078
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: October 1, 2002
    Publication date: January 8, 2004
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20030232826
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: May 29, 2003
    Publication date: December 18, 2003
    Applicant: Boehringer Ingelheim Pharmaciuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20030216383
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: October 1, 2002
    Publication date: November 20, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Weimin Liu, Denice M. Spero, David S. Thomson, Yancey D. Ward, Erick R.R. Young
  • Compounds useful as reversible inhibitors of cathepsin S
    Publication number: 20030158406
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I), (Ia) and (II), (IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: February 13, 2003
    Publication date: August 21, 2003
    Applicant: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Compounds useful as reversible inhibitors of cathepsin S
    Patent number: 6608057
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases.
    Type: Grant
    Filed: October 24, 2001
    Date of Patent: August 19, 2003
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Compounds useful as reversible inhibitors of cysteine proteases
    Patent number: 6525052
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: February 25, 2003
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R. R. Young
  • Novel compounds useful as reversible inhibitors of cysteine proteases
    Publication number: 20020137932
    Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: March 14, 2001
    Publication date: September 26, 2002
    Inventors: Younes Bekkali, Eugene R. Hickey, Weimin Liu, Usha R. Patel, Denice M. Spero, Sanxing Sun, David S. Thomson, Yancey D. Ward, Erick R.R. Young
  • Compounds useful as reversible inhibitors of cathepsin S
    Publication number: 20020091259
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Application
    Filed: February 24, 2002
    Publication date: July 11, 2002
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Tina Morwick, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
    Patent number: 6395897
    Abstract: Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: May 28, 2002
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Charles L. Cywin, Michel J. Emmanuel, Leah L. Frye, Denice M. Spero, David S. Thomson, Yancey D. Ward
  • Synthesis of alpha-methyl, alpha-substituted amino acids
    Patent number: 6043376
    Abstract: An improved process for making chiral, .alpha.-methylated, .alpha.-substituted amino acids of the formula I ##STR1## wherein Y is a hydrogen atom and R.sub.2 is the residue of a natural or unnatural amino acid, in which process an oxazolidinone of the formula II ##STR2## is formed by reacting a protected amino acid of the formula IA ##STR3## wherein Y is a protecting group, with an aldehyde of the formula RCHO, or an equivalent thereof, in the presence of a chlorinating agent and a Lewis acid.The group R.sub.2 is introduced into the oxazolidinone intermediate of formula II in a conventional manner, and subsequent hydrolysis and deprotection, both carried out in a conventional manner, yield the chiral, .alpha.-methylated, .alpha.-substituted amino acid.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: March 28, 2000
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Denice M. Spero, Suresh Kapadia, Elio Napolitano